All In Biotech

Drug Trial Radar · NCT06956196

Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Stapokibatrt in Children With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

May 2025

Primary completion

May 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
May 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • StapokibatrtBiological

    Stapokibatrt 1 or 2 ml,Subcutaneous injection(SC)

  • PlaceboOther

    Placebo of matching volume,Subcutaneous injection(SC)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving Eczema Area and Severity Index(EASI-75) at week 18Time frame: Up to week 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Children's Hospital Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.